Oncology

Latest News

FDA Approved | Image credit: chrisdorney – stock.adobe.com

Teliso-V Approved to Treat Advanced NSCLC With High c-Met Protein Overexpression

By Hayden E. Klein

May 14th 2025

Telisotuzumab vedotin (Teliso-V) gained FDA approval as a targeted therapy for patients with advanced non–small cell lung cancer (NSCLC) with high c-Met overexpression, offering new hope.

While CTCs were identified regardless of disease stage, the current study identified large variations in the presence of CTCs between nonmetastatic and metastatic disease | Image Credit: Innovative Creation - stock.adobe.com

Flow Cytometry Can Reliably Identify CTC in Melanoma

By AJMC Contributor

May 14th 2025

Jack & Sheryl Morris Cancer Center | Image credit: RWJBarnabas Health

New Jersey’s First Freestanding Cancer Hospital Opens in New Brunswick

By Pearl Steinzor

May 14th 2025

At 3 months, hospitalizations among patients enrolled in RSM were 19% lower vs historical controls. | Image Credit: Nuttapong punna - stock.adobe.com

Remote Symptom Monitoring Linked to Reduced Hospitalization Risk for Patients With Cancer

By Rose McNulty

May 14th 2025

Offline data augmentation can significantly enhance deep learning techniques, improving classification performance compared to models trained solely on original clinician skin images. | Image Credit: Alexander - stock.adobe.com

Optimized Deep Learning Model Classifies Smartphone Images of Malignant Skin Lesions

By AJMC Contributor

May 12th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

More News

October 24th 2017

Study: Prophylactic Up-Front Locoregional Surgery Has No Survival Advantage

Jaime Rosenberg

The study found that prophylactic locoregional surgery (LRS) for asymptomatic patients with small intestinal neuroendocrine tumors (SI-NETs) provided no survival advantage compared with delayed LRS.

October 23rd 2017

Increased Insurance Coverage Seen Under the ACA for Patients With Cancer

Jaime Rosenberg

A new study has found that uninsurance rates declined the most in patients with distant disease and with lung and bronchial cancer. Hispanic patients also saw a large decrease in uninsurance rates.

Podcast: This Week in Managed Care - Bipartisan ACA Deal and Other Health News

October 21st 2017

Podcast: This Week in Managed Care - Bipartisan ACA Deal and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

This Week in Managed Care: October 20, 2017

October 20th 2017

This Week in Managed Care: October 20, 2017

This week, the top managed care news included the bipartisan deal to stabilize the Affordable Care Act's insurance markets; coverage from the Academy of Managed Care Pharmacy 2017 Nexus; and a plan to reduce clinician burnout at the computer.

October 19th 2017

Kite Pharma's CAR T-Cell Treatment Approved, Cheaper Than Tisagenlecleucel

Surabhi Dangi-Garimella, PhD

Axicabtagene ciloleucel (Yescarta) has been approved to treat adult patients with diffuse large B-cell lymphoma who have not responded to or who have relapsed after at least 2 other kinds of treatment.

October 18th 2017

PD-1 Inhibitor Doubled Survival in Treatment-Naive Patients With mNSCLC

Surabhi Dangi-Garimella, PhD

The 2-year follow up results from the Keynote-024 trial were presented at the 18th World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer in Yokohama, Japan.

October 18th 2017

Increasing Levels of CD8+ TILs Prolong Survival in High-Grade Serous Ovarian Cancer

Jaime Rosenberg

There is a relationship between CD8+ tumor infiltrating lymphocytes (TILs) and high-grade serous ovarian carcinoma (HGSOC) survival, according to a new study published in JAMA Oncology.

October 17th 2017

PBMs: Their Role, the Problems, and How Practices Can Work With Them

Ray Bailey, RPh Ricky Newton, CPA

October 17th 2017

Positive Quality Interventions: An Innovative Platform for Oncology Practice Collaboration

Joshua Nubla, PharmD Neal Dave, PharmD Michael Reff, RPh, MBA

An in-depth look into a nationwide collaborative initiative to standardize and improve oncology dispensing practices for the benefit of patient/provider education, adherence, and overall care.

October 17th 2017

Looking Ahead at the Specialty Drug Pipeline After an Active Year of Approvals

Christina Mattina

Aimee Tharaldson, PharmD, of Express Scripts kicked off the Academy of Managed Care Pharmacy (AMCP) 2017 Nexus, held October 16-19 in Dallas, Texas, with a presentation on the pipeline of specialty pharmaceuticals in development.

October 17th 2017

UK Patients With Head and Neck Cancer Will Soon Have Access to Nivolumab

Jaime Rosenberg

The immunotherapy drug, made by Bristol-Myers Squibb, is recommended for use within the Cancer Drug Fund.

October 16th 2017

Trends in Hospital–Physician Integration in Medical Oncology

Jeffrey D. Clough, MD, MBA Michaela A. Dinan, PhD Kevin A. Schulman, MD

The authors used Medicare claims data to examine trends in hospital–physician integration in high-volume specialties, including medical oncology.

October 16th 2017

St. Jude Study Questions Efficacy of the Flu Vaccine in Children With Leukemia

Surabhi Dangi-Garimella, PhD

The study found that young patients with leukemia who have been vaccinated against the influenza virus are as susceptible to develop flu as their unvaccinated peers.

October 16th 2017

Pharmacy Team Engagement in Navigating the Revenue Cycle for High-Cost Medications in Patients With Cancer

Brandon R. Shank, PharmD, MPH, BCOP Phuoc Anh (Anne) Nguyen, PharmD, MS, BCPS Emily C. Pherson, PharmD, BCPS

With the clinical and financial implications of high-cost medications, and their impact on health system revenue, it is of utmost importance for all key stakeholders to be engaged in the complex revenue cycle.

October 16th 2017

Patients With Early Small Cell Lung Cancer Respond Favorably to Opdivo, Yervoy Combo

Jaime Rosenberg

The study showed that using tumor mutation burden (TMB) can be beneficial for predicting patient response to the combination of 2 immuno-oncology therapies.

October 13th 2017

Diagnosing and Treating Neutropenia: Q&A With Dr Daniel J. DeAngelo

Before treating certain patients, Daniel J. DeAngelo, MD, JD, of Harvard Medical School and the Dana-Farber Cancer Institute, will council them on the risk of developing neutropenia, which can result in hospitalization or even an intensive care stay.

October 13th 2017

AJMC®tv Interviews, October 2017

The Center for Biosimilars® Laura Joszt, MA

AJMC®TV interviews let you catch up on what’s new and important about changes in healthcare, with insights from key decision makers-from the clinician, to the health plan leader, to the regulator. When every minute in your day matters, AJMC®TV interviews keep you informed. Access the video clips at ajmc.com/interviews.

October 13th 2017

Medical World News®, October 2017

An update on the latest developments in the world of oncology care: product approvals, clinical developments, health policy changes, and more.

October 13th 2017

Stand Up To Cancer Awards $5.5 Million for Epigenetic Immunotherapy Trials

Jaime Rosenberg

While many lung and bladder cancer patients respond well to immunotherapy, they eventually succumb to the disease because the immune system can not detect the cancer cells. Two clinical trials will combine immunotherapy with epigenetic agents in order to allow the immune system to recognize and destroy the cancer cells.

October 13th 2017

Pharmacy's Changing Role as Cancer Care Transitions From Infused to Oral Therapies

Stacey McCullough, PharmD Ricky Newton, CPA

The advent of oral oncolytics has changed the pharmacy's role in patient care beyond compounding infusions. Pharmacy staff now routinely engage patients, assessing adherence and tolerance to therapy as well as helping them navigate prescription benefits.

October 11th 2017

Deficient Mismatch Repair Extends Disease-Free Survival in CRC

Jaime Rosenberg

Patients with stage III colon cancer with deficient DNA mismatch repair (MMR) genes who are treated with FOLFOX have a more favorable prognosis than those with proficient MMRs.

October 11th 2017

A Reproductive Endocrinologist Discusses Need to Cover Fertility Intervention in Cancer Care

Surabhi Dangi-Garimella, PhD

The American Journal of Managed CareÂ® spoke with Jane L. Frederick, MD, FACOG, a reproductive endocrinologist and fertility specialist, about the changing landscape of cancer treatment, partnering with oncologists, and helping patients gain financial assistance for their fertility preservation and treatment.

October 10th 2017

Study Shows Most Cases of Liver Cancer Can Be Prevented

Jaime Rosenberg

Study focused on liver cancer cases, over time, in different locations and the main causes.

October 9th 2017

Oncologists Skeptical of Omitting Radiation Therapy in Early-Stage Breast Cancer in Older Women

Surabhi Dangi-Garimella, PhD

A new study highlights how the beliefs of surgeons and radiation oncologists influences radiotherapy use in early-stage breast cancer among older women.

Dr Michael Kolodziej on How Technology Will Improve Patient Access to Clinical Trials

October 9th 2017

Dr Michael Kolodziej on How Technology Will Improve Patient Access to Clinical Trials

Technological advances will lead to improvements in clinical trials and greater participation in trials by patients, explained Michael Kolodziej, MD, national medical director of managed care strategy at Flatiron Health.

Podcast: This Week in Managed Care - Finding a New HHS Secretary, and Other Health News

October 7th 2017

Podcast: This Week in Managed Care - Finding a New HHS Secretary, and Other Health News

Every week, The American Journal of Managed CareÂ® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.

October 6th 2017

CDC Calls Attention to Connections Between Obesity and Cancer

The US Preventive Services Task Force already has recommendations for screening and intervention for obesity, but they often are not followed.

This Week in Managed Care: October 6, 2017

October 6th 2017

This Week in Managed Care: October 6, 2017

This week, the top managed care stories included speculation regarding who would replace Tom Price, MD, as HHS secretary; a report on breast cancer mortality trends and racial disparities from 1989 to 2015; and the FDA announced new strategies to improve patient access to less expensive drugs.

October 6th 2017

European Study Questions Survival, QOL Benefit of Marketed Cancer Drugs

Surabhi Dangi-Garimella, PhD

A new study in the journal BMJ concludes that most oncology drugs approved by the European Medicines Agency between 2009 and 2013 failed to display a benefit on survival or quality of life, even at 3.3 years following market entry.

Tesh Khullar: Community Oncologists Have to Be Business Experts to Stay Alive

October 6th 2017

Tesh Khullar: Community Oncologists Have to Be Business Experts to Stay Alive

As the health system evolves it will become increasingly important that practices understand business, explained Tesh Khullar, senior vice president of provider solutions at Flatiron Health.

...

63 64 65 66 67 68 69 70 71

...

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions